Brief: Mersana Therapeutics Announces Topline Data From Uplift Clinical Trial In Patients With Platinum-Resistant Ovarian Cancer And Strategic Reprioritization

Mersana Therapeutics

27/07/2023 12:09

Mersana Therapeutics Inc  MRSN.O :
    * MERSANA THERAPEUTICS ANNOUNCES TOPLINE DATA FROM UPLIFT
CLINICAL
TRIAL IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER AND
STRATEGIC REPRIORITIZATION
    * MERSANA THERAPEUTICS INC - COMPANY REALIGNS FOCUS AND
SIGNIFICANTLY REDUCES EXPENSES TO EXTEND CASH RUNWAY INTO 2026
    * MERSANA THERAPEUTICS INC - UPLIFT CLINICAL TRIAL DID NOT
MEET
ITS PRIMARY ENDPOINT
    * MERSANA THERAPEUTICS INC - NECESSITATES REDUCING OUR
WORKFORCE
BY APPROXIMATELY 50%
    * MERSANA THERAPEUTICS INC - PLAN TO COMPLETE DOSE
ESCALATION
PORTION OF OUR PHASE 1 CLINICAL TRIAL OF XMT-1660 IN 2023
    * MERSANA THERAPEUTICS INC - RESTRUCTURING PLAN INCLUDES A
WIND-DOWN OF UPRI-RELATED DEVELOPMENT ACTIVITIES
    * MERSANA THERAPEUTICS INC -  PLAN TO INITIATE DOSE
EXPANSION
PORTION OF PHASE 1 CLINICAL TRIAL OF XMT-1660 IN 2024
    * MERSANA THERAPEUTICS - IF ANALYSES OF DATA ENABLE
IDENTIFICATION
OF A PATH FORWARD FOR UPRI, COMPANY WILL CONSIDER STRATEGIC
ALTERNATIVES FOR ASSET
    * MERSANA THERAPEUTICS INC - SAFETY AND TOLERABILITY DATA IN
UPLIFT WERE GENERALLY CONSISTENT WITH PRIOR DISCLOSURES

Source text for Eikon:  ID:nGNX9XbYF2 
Further company coverage:  MRSN.O